INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

Thank goodness real science and health experts are working tirelessly to combat the misinformation and disinformation about ...

A breakthrough clinical trial in Japan reveals that a vitamin B3 derivative significantly improves symptoms of the rare ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

A phase 3 clinical trial investigating ST-100 for the treatment of dry eye disease did not meet its primary endpoint but ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE ...

Bojungikgi-tang improved anorexia and atopic dermatitis symptoms in a randomized trial, with effects linked to gut microbiome ...

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced ...

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and ...

Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...